Showing 1 - 9 of 9 trials – Showing only trials currently accepting patients

• CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

  Stanford is currently accepting patients for this trial.

• Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

  Stanford is currently accepting patients for this trial.

• Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease

  Stanford is currently accepting patients for this trial.

• A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

  Stanford is currently accepting patients for this trial.

• Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

  Stanford is currently accepting patients for this trial.

• Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

  Stanford is currently accepting patients for this trial.

• A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

  Stanford is currently accepting patients for this trial.

• A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

  Stanford is currently accepting patients for this trial.

• IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

  Stanford is currently accepting patients for this trial.